Finnish congenital nephrotic syndrome: genes and variants
Explore variant evidence for Finnish congenital nephrotic syndrome across 2 analyzed proteins (NPHS1, NPHS2). Linked ClinVar records include 71 pathogenic or likely pathogenic variants, 152 variants of uncertain significance and 60 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Counts refer to the selected disease label.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Finnish congenital nephrotic syndrome
NPHS1: Nephrin
It forms a key structural and signaling component of the slit diaphragm between glomerular podocyte foot processes. Biallelic loss-of-function variants cause congenital nephrotic syndrome of the Finnish type with massive protein loss beginning early in life.
70 ClinVar pathogenic / likely pathogenic and 211 uncertain variants in NPHS1 have source records linked to Finnish congenital nephrotic syndrome. Association strength is not clinical gene validity.
NPHS2: Podocin
It organizes nephrin-containing slit-diaphragm complexes in podocytes and helps maintain the glomerular filtration barrier. Biallelic pathogenic variants are a major cause of steroid-resistant nephrotic syndrome and focal segmental glomerulosclerosis.
1 ClinVar pathogenic / likely pathogenic and 1 uncertain variants in NPHS2 have source records linked to Finnish congenital nephrotic syndrome. Association strength is not clinical gene validity.
ClinVar pathogenic and likely pathogenic variants linked to Finnish congenital nephrotic syndrome
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| NPHS1 P368L | 368 | Ig-like C2-type 4 | Pathogenic / likely pathogenic (★★) |
| NPHS1 P368S | 368 | Ig-like C2-type 4 | Pathogenic / likely pathogenic (★★) |
| NPHS1 V736A | 736 | Extracellular | Pathogenic / likely pathogenic (★★) |
| NPHS1 S366R | 366 | Ig-like C2-type 4 | Pathogenic / likely pathogenic (★★) |
| NPHS1 R711S | 711 | Extracellular | Pathogenic / likely pathogenic (★★) |
| NPHS1 R711H | 711 | Extracellular | Pathogenic / likely pathogenic (★★) |
| NPHS1 C623F | 623 | Ig-like C2-type 6 | Pathogenic / likely pathogenic (★★) |
| NPHS1 V709G | 709 | Extracellular | Pathogenic / likely pathogenic (★★) |
| NPHS2 R168H | 168 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| NPHS1 P167L | 167 | Ig-like C2-type 2 | Pathogenic / likely pathogenic (★★) |
| NPHS1 R367C | 367 | Ig-like C2-type 4 | Pathogenic / likely pathogenic (★★) |
| NPHS1 L587R | 587 | Ig-like C2-type 6 | Pathogenic / likely pathogenic (★★) |
| NPHS1 G796R | 796 | Ig-like C2-type 7 | Pathogenic / likely pathogenic (★★) |
| NPHS1 G867D | 867 | Ig-like C2-type 8 | Pathogenic / likely pathogenic (★★) |
| NPHS1 L96V | 96 | Ig-like C2-type 1 | Pathogenic / likely pathogenic (★★) |
| NPHS1 G270C | 270 | Ig-like C2-type 3 | Pathogenic / likely pathogenic (★★) |
| NPHS1 S572N | 572 | Ig-like C2-type 6 | Pathogenic / likely pathogenic (★★) |
| NPHS1 G796E | 796 | Ig-like C2-type 7 | Pathogenic / likely pathogenic (★★) |
| NPHS1 R831C | 831 | Extracellular | Pathogenic / likely pathogenic (★★) |
| NPHS1 D105N | 105 | Ig-like C2-type 1 | Pathogenic / likely pathogenic (★★) |
| NPHS1 R802W | 802 | Ig-like C2-type 7 | Pathogenic / likely pathogenic (★★) |
| NPHS1 R888K | 888 | Ig-like C2-type 8 | Pathogenic / likely pathogenic (★★) |
| NPHS1 Y977C | 977 | Fibronectin type-III | Pathogenic / likely pathogenic (★★) |
| NPHS1 M1T | 1 | Pathogenic / likely pathogenic (★★) | |
| NPHS1 D310N | 310 | Ig-like C2-type 3 | Pathogenic / likely pathogenic (★★) |
| NPHS1 S350P | 350 | Ig-like C2-type 4 | Pathogenic / likely pathogenic (★★) |
| NPHS1 R407W | 407 | Ig-like C2-type 4 | Pathogenic / likely pathogenic (★★) |
| NPHS1 R460Q | 460 | Ig-like C2-type 5 | Pathogenic / likely pathogenic (★★) |
| NPHS1 P519S | 519 | Ig-like C2-type 5 | Pathogenic / likely pathogenic (★★) |
| NPHS1 R743C | 743 | Ig-like C2-type 7 | Pathogenic / likely pathogenic (★★) |
| NPHS1 A806D | 806 | Ig-like C2-type 7 | Pathogenic / likely pathogenic (★★) |
| NPHS1 S910P | 910 | Ig-like C2-type 8 | Pathogenic / likely pathogenic (★★) |
| NPHS1 V822M | 822 | Extracellular | Pathogenic / likely pathogenic (★★) |
| NPHS1 R711C | 711 | Extracellular | Pathogenic / likely pathogenic (★) |
| NPHS1 V736M | 736 | Extracellular | Pathogenic / likely pathogenic (★) |
| NPHS1 V834F | 834 | Extracellular | Pathogenic / likely pathogenic (★) |
| NPHS1 P674L | 674 | Extracellular | Pathogenic / likely pathogenic (★) |
| NPHS1 C160S | 160 | Ig-like C2-type 2 | Pathogenic / likely pathogenic (★) |
| NPHS1 L334P | 334 | Extracellular | Pathogenic / likely pathogenic (★) |
| NPHS1 A672T | 672 | Extracellular | Pathogenic / likely pathogenic (★) |
| NPHS1 C265R | 265 | Ig-like C2-type 3 | Pathogenic / likely pathogenic (★) |
| NPHS1 C465Y | 465 | Ig-like C2-type 5 | Pathogenic / likely pathogenic (★) |
| NPHS1 S569R | 569 | Ig-like C2-type 6 | Pathogenic / likely pathogenic (★) |
| NPHS1 P838T | 838 | Ig-like C2-type 8 | Pathogenic / likely pathogenic (★) |
| NPHS1 C863R | 863 | Ig-like C2-type 8 | Pathogenic / likely pathogenic (★) |
| NPHS1 V957E | 957 | Fibronectin type-III | Pathogenic / likely pathogenic (★) |
| NPHS1 G967R | 967 | Fibronectin type-III | Pathogenic / likely pathogenic (★) |
| NPHS1 P243L | 243 | Ig-like C2-type 3 | Pathogenic / likely pathogenic (★) |
| NPHS1 R976S | 976 | Fibronectin type-III | Pathogenic / likely pathogenic (★) |
| NPHS1 N673K | 673 | Extracellular | Pathogenic / likely pathogenic |
| NPHS1 A739V | 739 | Extracellular | Pathogenic / likely pathogenic |
| NPHS1 I742T | 742 | Ig-like C2-type 7 | Pathogenic / likely pathogenic |
| NPHS1 R802P | 802 | Ig-like C2-type 7 | Pathogenic / likely pathogenic |
| NPHS1 W64S | 64 | Ig-like C2-type 1 | Pathogenic / likely pathogenic |
| NPHS1 C528F | 528 | Ig-like C2-type 5 | Pathogenic / likely pathogenic |
| NPHS1 L643P | 643 | Extracellular | Pathogenic / likely pathogenic |
| NPHS1 W681C | 681 | Extracellular | Pathogenic / likely pathogenic |
| NPHS1 L832P | 832 | Extracellular | Pathogenic / likely pathogenic |
| NPHS1 I171N | 171 | Ig-like C2-type 2 | Pathogenic / likely pathogenic |
| NPHS1 I173N | 173 | Ig-like C2-type 2 | Pathogenic / likely pathogenic |
Showing 60 of 71.
Uncertain variants prioritized for review in Finnish congenital nephrotic syndrome
| Variant | Position | Protein part | Clinical label | Evidence |
|---|---|---|---|---|
| NPHS1 S572G | 572 | Ig-like C2-type 6 | Conflicting reports (★) | +6: 3 other pathogenic changes within 3 positions; S572N at the same position is pathogenic; seen in 4.1e-06 of gnomAD DNA copies; REVEL 0.666 |
Which prediction tools work for Finnish congenital nephrotic syndrome
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- CATVariant: 97 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- REVEL: 96 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MutPred: 95 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- AlphaMissense: 94 out of 100
- PolyPhen-2: 94 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- ESM1b (LLR): 92 out of 100
- CADD: 91 out of 100
- SIFT: 90 out of 100
- phyloP: 87 out of 100
- MetaLR: 81 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaSVM: 80 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- SpliceAI: 52 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- Pangolin: 46 out of 100 (learned from overlapping clinical labels, so this is optimistic)
Same protein, different disease
- Nephrotic syndrome also has ClinVar records linked to NPHS2 variants; they fall mostly in different places as the Finnish congenital nephrotic syndrome variants (30 pathogenic / likely pathogenic).
- Steroid-resistant nephrotic syndrome also has ClinVar records linked to NPHS2 variants; they fall mostly in different places as the Finnish congenital nephrotic syndrome variants (8 pathogenic / likely pathogenic).
- Idiopathic nephrotic syndrome also has ClinVar records linked to NPHS2 variants; they fall mostly in different places as the Finnish congenital nephrotic syndrome variants (5 pathogenic / likely pathogenic).
Diseases related to Finnish congenital nephrotic syndrome
- Nephrotic syndrome, also linked to NPHS1 and NPHS2
- Focal segmental glomerulosclerosis, also linked to NPHS1 and NPHS2
- Steroid-resistant nephrotic syndrome, also linked to NPHS2
- Idiopathic nephrotic syndrome, also linked to NPHS2
- Kidney disorder, also linked to NPHS1
Frequently asked questions
Which genes have records linked to Finnish congenital nephrotic syndrome?
This view contains 2 analyzed proteins: NPHS1, NPHS2. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 71 pathogenic or likely pathogenic variants, 152 variants of uncertain significance and 60 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 1 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 287 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center